News Search Results
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced the initial data of the first-in-human trial of IBI3003, a novel trispecific antibody targeting G protein-coupled
More news about: Innovent Biologics
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List
More news about: Innovent Biologics
Dec 05, 2025, 14:37 ET Salt Lake City Oculoplastic Surgeon Dr. Kian Eftekhari to Present Innovative Ptosis Technique at International ABAM Conference
completed his ophthalmology residency at the University of Pennsylvania's Scheie Eye Institute and pursued an additional two years of subspecialty fellowship training in oculoplastic and facial surgery in Salt Lake City.Dr. Eftekhari is board-certified by the American Board of Ophthalmology and is an
More news about: Eyelid Center of Utah
Dec 05, 2025, 08:00 ET Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Dec 04, 2025, 04:16 ET Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials
More news about: MS Pharma
Dec 04, 2025, 04:15 ET Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for the MENA Region
leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials
More news about: MS Pharma
Dec 03, 2025, 08:56 ET Dicom Systems Processes 124 Billion Medical Images Annually and Achieves ISO 27001 Certification, CE Mark, Expands Digital Pathology and Reseller Partnerships
Unifier platform reflects growing demand for scalable interoperability across radiology, cardiology, ophthalmology, and digital pathology. Deployed at over 630 sites globally, Unifier enables secure, efficient data exchange between imaging modalities, PACS, EHR
More news about: Dicom Systems
Dec 03, 2025, 08:00 ET Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
a paid endorsement. Naomi Watts was compensated for this quote.1 How hormones can affect eyes and vision. American Academy of Ophthalmology. (2018, November 12).
More news about: Johnson & Johnson MedTech
Dec 03, 2025, 08:00 ET Stellaromics Establishes First U.S. Pyxa™ 3D Spatial Transcriptomics Site at UC Irvine
laboratory of Dr. Rui Chen, Professor of Ophthalmology at the Gavin Herbert Eye Institute, Robert M. Brunson Center for Translational Vision Research. Internationally recognized for his work mapping
More news about: Stellaromics
Dec 03, 2025, 05:00 ET Formosa Pharmaceuticals Announces Licensing Agreement with Rxilient, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
Pharmaceuticals, Inc.Formosa Pharmaceuticals, Inc. (6838.TW) is a clinical stage biotechnology company with primary focus in the areas of ophthalmology and oncology. The company's proprietary nanoparticle formulation technology (APNT®), through which APP13007 was developed, improves the
More news about: Formosa Pharmaceuticals Inc.,
Dec 02, 2025, 19:43 ET Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Dec 02, 2025, 16:47 ET Avetra Launches as a Next-Generation, Site-Centric CRO Transforming Clinical Trial Operations
Network & Integrated Laboratory CapabilitiesAvetra's network spans leading research sites across gastroenterology, endocrinology, ophthalmology, obesity, vaccines, and additional therapeutic areas. Its central laboratory division will further streamline specimen handling, logistics, and
More news about: Avetra, Inc
Dec 02, 2025, 10:00 ET Avisi Technologies Announces First Patient Implanted with VisiPlate® Glaucoma Treatment Device in the SAPPHIRE Trial
options. VisiPlate® has been previously studied in the VITA Trial with long-term follow up data presented at the 2025 American Academy of Ophthalmology annual meeting."VisiPlate is an advanced technology designed to maximize patients' quality of life. Dr. Snyder's successful VisiPlate surgery
More news about: Avisi Technologies, Inc.
Dec 02, 2025, 06:42 ET Prefilled Syringes (PFS) Market Size to Grow USD 32.98 Billion by 2035 at a CAGR 13.75 | Vantage Market Research
low-molecular-weight heparin (LMWH) are major contributors, supported by high hospital usage and at-home post-surgical care management.Ophthalmology: Rising incidence of retinal disorders and growing use of intravitreal injections drive uptake of precision-engineered prefilled syringes designed
More news about: Vantage Market Research
Dec 02, 2025, 06:40 ET Prescription Drugs Market Poised for Substantial Growth, Driven by Novel Therapies and Evolving Regulatory Landscape: Reaching US$2.15 Trillion by 2032
market share, driven by a growing patient pool and the successful launch of biologic therapies. Other significant therapeutic areas, including Ophthalmology, Respiratory, Gastroenterology, and Gynecology, collectively account for the remainder, addressing a wide spectrum of patient
More news about: DataM Intelligence 4 Market Research LLP
Nov 28, 2025, 04:06 ET China's First Domestic IL-23p19 Monoclonal Antibody: Innovent's PECONDLE® (Picankibart Injection) Received NMPA Approval
aiming to address unmet clinical needs such as drug resistance and disease recurrence. Innovent will continue to expand its innovative portfolio in ophthalmology, autoimmune diseases, and cardiovascular and metabolic (CVM) conditions, with the aim to help more people achieve healthier lives."
More news about: Innovent Biologics
Nov 27, 2025, 00:14 ET B Prabhakaran visits Lloyds Kali Ammal Memorial (LKAM) Hospital to celebrate the milestone of 300th Baby Delivery
operates as a 30-bed multispecialty centre offering medical services across emergency care, obstetrics, paediatrics, general medicine, dentistry and ophthalmology, supported by modern diagnostics and a dedicated clinical team. The hospital serves between 100 and 150 patients each day and has become a trusted
More news about: Lloyds Kali Ammal Memorial (LKAM) Hospital
Nov 26, 2025, 14:19 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Nov 26, 2025, 14:13 ET Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Nov 26, 2025, 10:15 ET Intraocular Lens Market worth $6.17 billion by 2030 with 6.0% CAGR | MarketsandMarkets™
Ophthalmology Drugs Market
More news about: MarketsandMarkets
Nov 26, 2025, 08:00 ET SECTRA LAUNCHES ITS BUILT-IN REPORTING SOLUTION IN THE US--ACCELERATES DIAGNOSTICS FOR IMPROVED PATIENT CARE
Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, genomics and ophthalmology), and a robust VNA. Over the last consecutive twelve years, Sectra has been awarded Best in KLAS for highest
More news about: Sectra
Nov 26, 2025, 01:48 ET Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Nov 25, 2025, 22:51 ET FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)
U.S. as well as global Emerging Markets. Sun Pharma's high-growth global Innovative Medicines portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Nov 25, 2025, 14:01 ET From Tradition to Tomorrow: PIH Health Good Samaritan Hospital Celebrates 140 Years of Excellence
cardiothoracic surgery), women's health (obstetrics, gynecology, neonatal intensive care, and gynecologic oncology), breast care, orthopedic surgery, ophthalmology, oncology, digestive diseases, kidney stone treatment, and more.PIH Health Good Samaritan Hospital remains a pillar of the Los Angeles medical
More news about: PIH Health
Nov 25, 2025, 09:45 ET To Educate the Public and Raise Awareness, Prevent Blindness Declares Fifth Annual Geographic Atrophy Week as Dec. 1-7, 2025
Advancements in Treatments for Geographic Atrophy," featuring Rajeev S. Ramchandran, MD, MBA, Associate Professor of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center."
More news about: Prevent Blindness